Approval · Notice of Compliance 16202 · 2014
EXELON PATCH: Notice of Compliance 16202
Issued October 20, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16202
- Date
- October 20, 2014
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength for moderately severe alzheimer's dementia. revised indication for approved strengths to include patients with moderately severe alzheimer's dementia
- Therapeutic class
- Cholinesterase inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EXELON PATCH | 02432803 | Marketed |
Medicinal ingredients
- RIVASTIGMINE 27 MG per PATCH